Start
•
Completion

Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer

CompletedRegisteredCTG

The primary purpose of this study is to see if it is safe to give patients with cancer a low dose of the FDA approved anesthetic drug ketamine at the same time they receive radiation, chemotherapy, and/or surgery for their cancer treatment to treat depression and its effects

Details

Prospective, single-centre, double-blind, randomised, parallel two-arm feasibility study assessing nightly oral ketamine 1.0 mg/kg versus placebo for depression in patients undergoing curative-intent cancer therapy.

Study treatment given once daily for 12 weeks with psychosocial and symptom measures every two weeks during treatment and monthly during a five-month follow-up; placebo arm participants may opt to receive open-label ketamine after completion.

Topics:Depressive Disorders

Registry

Registry linkNCT02836288